AstraZeneca
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Descriptive Study of the Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Biologic Therapy, a Post Authorization Safety Study
Completed
- Conditions
- NeoplasmsAsthma
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14000
- Registration Number
- NCT04991805
- Locations
- π¬π§
Research Site, Norwich, Norfolk, United Kingdom
Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer
Completed
- Conditions
- Fallopian Tube Cancer
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 605
- Registration Number
- NCT04991051
- Locations
- π¦πͺ
Research Site, Alain, United Arab Emirates
Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens
Phase 2
Completed
- Conditions
- Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 95
- Registration Number
- NCT04989816
- Locations
- π¨π³
Research Site, Zhengzhou, China
Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
Phase 2
Completed
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Other: Placebo
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 711
- Registration Number
- NCT04986202
- Locations
- πΉπ·
Research Site, Izmir, Turkey
Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2848
- Registration Number
- NCT04973449
- Locations
- π¬π§
Research Site, Truro, United Kingdom
IBS-C Questionnaire Study
Completed
- Conditions
- Functional ConstipationIrritable Bowel Syndrome With Constipation
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT04968652
- Locations
- π¨π³
Research Site, Zhengzhou, China
Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia
Completed
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1088
- Registration Number
- NCT04964908
- Locations
- π¦πͺ
Research Site, Abu Dhabi, United Arab Emirates
A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 411
- Registration Number
- NCT04964557
- Locations
- πͺπΈ
Research Site, Zaragoza, Spain
Technology-Assisted Cholesterol Trial in Consumers (TACTiC)
Phase 3
Completed
- Conditions
- High Cholesterol
- Interventions
- Combination Product: 5 mg rosuvastatin calcium with a Web App (combination product)
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1196
- Registration Number
- NCT04964544
- Locations
- πΊπΈ
Research Site, Indianapolis, Indiana, United States
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
Phase 3
Active, not recruiting
- Conditions
- ER-Positive HER2-Negative Breast Cancer
- Interventions
- Drug: AZD9833 PlaceboDrug: Luteinizing hormone-releasing hormone (LHRH) agonist
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 315
- Registration Number
- NCT04964934
- Locations
- π¬π§
Research Site, Taunton, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath